沃森生物 (300142.SZ)

11.38 0.00 (0.00%) 收市：03:04PM CST

沃森生物

No. 395 Kexin Road
Wuhua District
Kunming 650101
China
86 87 1683 30860
https://www.walvax.com

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 2,388

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Runsheng Jiang	Director & President	無	無	1957
Ms. Hua Zhou	Chief Financial Officer	無	無	1967
Ms. Yun Yan Wu	Director of Operations	無	無	1982
Mr. Jin Long Zhao	Chief Investment Officer	無	無	1973
Ms. Lin Yuan	Technical Director	無	無	1982
Mr. Wei Yao	Marketing Director	無	無	1972
Mr. Qing Gongsun	Director of Human Resources	無	無	1966
Mr. Jiankang Zhang	VP & Director	無	無	1957
Mr. Shao Zhong Dong	VP & Director	無	無	1968
Mr. Yu Ran Liu	Board Secretary	無	無	1989

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 CNY。

描述

Walvax Biotechnology Co., Ltd., researches, develops, produces, and markets vaccines in China. The company offers SARS-CoV-2 mRNA vaccine, an immunization to prevent COVID-19 to individuals 18 years of age and older; 13-valent pneumococcal polysaccharide conjugate vaccine, an invasive diseases caused by streptococcus pneumoniae for use in infants and children 6 weeks through 5 years of age; and recombinant human papillomavirus bivalent vaccine, for the prevention of cervical cancers and precancerous lesions caused by human; 23-valent pneumococcal polysaccharide vaccine, for individuals age 2 years of pneumococcal diseases; ACYW135 meningococcal polysaccharide vaccine, for the prevention of invasive meningococcal diseases; Group A and C meningococcal polysaccharide vaccine, for in adults and children over the age of 2 years and adults to prevent disease caused by the bacterium neisseria meningitidis; Group A and Group C meningococcal conjugate vaccine, for the prevention of invasive meningococcal diseases caused by Neisseria meningitidis serogroups A and C for children 3 months through 5 years of age. It also provides haemophilus influenzae type b conjugate vaccine, for the prevention of invasive infections for children 2 months through 5 years of age; diphtheria, tetanus, and acellular pertussis combined vaccine, for diphtheria and tetanus for infants and children 3 months through 6 years of age. Walvax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Kunming, China.

公司管治

截至 2024年6月29日 止，沃森生物 的 ISS 管治質素評分為 2。 Pillar 分數正在審核中：5；董事會：2；股東權利：1；現金賠償：6。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。